Benjamin Tschumi

Debiopharm (Switzerland) — Switzerland

Immunology and Microbiology · Life Sciences

9h-index1.1kcitations16works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(9), Immunotherapy and Immune Responses(6), CAR-T cell therapy research(6), T-cell and B-cell Immunology(4), Cancer Immunotherapy and Biomarkers(3)

Publications16 total

Abstract 2303: The WEE1 inhibitor Debio 0123 enhances the efficacy of standard of care DNA damaging agents in lung cancer models
Cancer Research·2022· 1 cited
The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function
Cell Metabolism·2022· 180 citedOpen Access
47MO Metabolic intervention during CAR T-cell manufacturing improves persistence and antitumor efficacy
Annals of Oncology·2021Open Access
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
Nature Immunology·2021· 395 citedOpen Access
Enforced PGC-1α expression promotes CD8 T cell fitness, memory formation and antitumor immunity
Cellular and Molecular Immunology·2020· 160 citedOpen Access
Development of Advanced Human Immune System Mouse Models for Pre-Clinical Research in Immuno-oncology
Annals of Oncology·2019
Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle
Nature Immunology·2019· 3 citedOpen Access
Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control
Frontiers in Immunology·2019· 39 citedOpen Access
Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle
Nature Immunology·2019· 69 cited
Correction to: CART cells are prone to Fas- and DR5-mediated cell death
Journal for ImmunoTherapy of Cancer·2018· 9 citedOpen Access
CART cells are prone to Fas- and DR5-mediated cell death
Journal for ImmunoTherapy of Cancer·2018· 80 citedOpen Access
Harnessing iNKT and CD8 T cells for Immunotherapy of Cancer
IRIS·2018Open Access
Mammalian Target of Rapamycin Complex 2 Controls CD8 T Cell Memory Differentiation in a Foxo1-Dependent Manner
Cell Reports·2016· 132 citedOpen Access
Inhibition of mTORC2/Akt signaling to enhance the therapeutic potential of CD8 T cells
Journal for ImmunoTherapy of Cancer·2015Open Access
Mammalian Target of Rapamycin Complex 1 Orchestrates Invariant NKT Cell Differentiation and Effector Function
The Journal of Immunology·2014· 69 cited
Tumor targeting of innate and adaptive immunity by the adoptive cell transfer of engineered T lymphocytes co-expressing iNKT and tumor-specific MHC-I TCRs
Journal for ImmunoTherapy of Cancer·2014Open Access

Frequent Co-authors

Pedro Romero(13), Alena Donda(10), Lianjun Zhang(8), Fabien Franco(6), Ping‐Chih Ho(5), Mathias Wenes(4), Nina Dumauthioz(4), Jean‐Pierre Mach(4), Bastien Marti(3), Markus A. Rüegg(3), Michael N. Hall(3), Haiping Wang(2), Alison Jaccard(2), Tania Wyss(2), Noelia Maldonado‐Pérez(2), Anouk Lepez(2), Patrice Waridel(2), Denis Migliorini(2), Sophia Y. Lunt(2), Isabel C. López‐Mejía(2)